Patents by Inventor Mohammed Saleh Shekhani

Mohammed Saleh Shekhani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLUORESCENCE POLARIZATION hERG ASSAY
    Publication number: 20120231541
    Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: David Piper, Stephen Hess, Mohammed Saleh Shekhani, Thomas Livelli, Zhong Zhong, Steve Duff, Kurt Vogel
  • Fluorescence polarization hERG assay
    Patent number: 8133695
    Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: March 13, 2012
    Assignee: Life Technologies Corporation
    Inventors: David Piper, Kurt Vogel, Mohammed Saleh Shekhani, Stephen Hess, Steve Duff, Thomas Livelli, Zhong Zhong
  • FLUORESCENCE POLARIZATION hERG ASSAY
    Publication number: 20090253148
    Abstract: Disclosed are assays, methods, and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. In particular, whether a test compound has the effect to prolong the Q-T interval as measured by an electrocardiogram in a human. The assays, methods, and kits disclosed herein make use of the binding interaction between novel fluorescent tracers and the hERG K+ channel, and the propensity of a test compound to influence that binding interaction.
    Type: Application
    Filed: February 27, 2009
    Publication date: October 8, 2009
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: David Piper, Stephen Hess, Mohammed Saleh Shekhani, Thomas Livelli, Zhong Zhong, Steve Duff, Kurt Vogel
  • Polymyxin B conjugates
    Patent number: 6579696
    Abstract: Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Methods for treating acute infections with advantages over current therapeutic approaches are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 17, 2003
    Assignee: Promega Corporation
    Inventors: Mohammed Saleh Shekhani, Robert W. Schatz, Charles Pugh, Nicholas Panasik, Jr., Douglas Stafford
  • Compounds that bind bacterial pili
    Patent number: 5998381
    Abstract: Diagnostics and treatments for bacterial infection are disclosed. The treatments prevent bacteria from adhering to host cells by interfering with the binding of the bacteria to cell receptors. Compounds that inhibit bacterial adherence to cells are engineered to be readily modified for best efficacy with different modes of treatment. The compounds can be readily modified for use to identify bacteria according to their cell binding specificities.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: December 7, 1999
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: Mohammed Saleh Shekhani, Joseph R. Firca, Byron Anderson